# US 2006/0153825 A1 · Use of protein histidine phosphatase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153825 A1
- Document ID: US20060153825A1
- Status: Published application
- Kind: A1
- Application number: 10/471,100
- Filed: 2002-03-04
- Published: 2006-07-13
- Earliest claimed: 2001-03-08
- Assignees: Merck Patent GmbH
- Inventors: Roland Kellner; Susanne Klumpp
- Web page: https://patentgrep.com/patent/US20060153825A1

## CPC

- C12N 9/88: Lyases (4.)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C12N 9/16: acting on ester bonds (3.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the use of polypeptides with protein histidine phosphatase activity derived from mammalians, antibodies directed against them and DNA or RNA sequences complementary to mRNA sequences encoding polypeptides with protein histidine phosphatase activity for the modulation of ATP-citrate lyase and treatment of correlated pathophysiologic functions.

## Claims

### Claim 1

Use of a polypeptide having the biological activity of a Protein Histidine Phosphatase (PHP) which has a high specificity for phosphohistidine or a homologue variant for the modulation of ATP-citrate-lyase (EC 4.1.3.8) activity.

### Claim 2 (depends on 1)

Use of a polypeptide according to claim 1, having a molecular weight of 13.000-15.000,

### Claim 3 (depends on 1)

Use of a polypeptide according to claim 1, whereas the polypeptide comprises at least the amino acid sequence motif selected from the group of
I)
DCECLGGGRISHQSQDX“KIHVYGYSMX2YGX3AQH
wherein X1 = K or R, X2 = A or G and X3 = PorRor
II)
DCECLGGGRISHQSQD
or
III)
(M)AVADLALIPDVDIDSDGVFKYVLIRVHSAPRSGAPAAESKE
IVRGYKWAEYHADIYDKVSGDMQKQGCDCECLGGGRISHQSQDK
KIHVYGYSMAYGPAQH AISTEKIKAKYPDYEVTWANDGY.

### Claim 4 (depends on 1)

Use of an antibody or a fragment thereof directed to a polypeptide having a protein histidine phosphatase activity according to claim 1 for the modulation of ATP-citrate-lyase (EC 4.1.3.8) activity.

### Claim 5

A DNA sequence complementary to the mRNA sequence of protein histidine phosphatase having at least one of the following sequences
I)
TACCGCCACC GCCTGGAGCG AGAGTAAGGA CTACACCTGT
AGCTGAGGCT GCCGCAGAAG TTCATACACG ACTAGGCTCA
GGTGAGCCGA GGGGCGAGGC CCCGAGGCCG ACGTCTCTCG
TTCCTCTAGC ACGCGCCGAT GTTCACCCGA CTCATGGTAC
GCCTGTAGAT GCTGTTTCAC AGCCCGCTGT ACGTGTTCGT
TCCGACGCTG ACACTCACAG ACCCGCCGCC CGCGTAGAGG
GTGGTCTCAG
TCCTGTTCTT CTAAGTGCAC ATGCCGATAA GGTACCGGAT
ACCAGGACGG GTCGTGCGGT AAAGTTGACT CTTTTAGTTTC
GGTTCATGGG GCTGATGCTC CAGTGGACCC GATTGCTGCC
GATG
II)
CTGACACTCA CAGACCCGCC GCCCGCGTAG AGGGTGGTCT
CAGTCCTG
Ill)
CTGACACTCA CAGACCCGCC GCCCGCGTAG AGGGTGGTCT
CAGTCCTGTT CTTCTAAGTG CACATGCCGA TAAGGTACCG
GATACCAGGA CGGGTCGTG
IV)
ATGGTACGCC TGTAGATGCT GTTTCACAGC CCGCTGTACG
TCTTCGTTCC GACGCTGACA CTCACAGACC CGCCGCCCGC
GTAGAGGGTG GTCTCAGTCC TGTTCTTCTA AGTGCACATG
CCGATAAGGT AC

### Claim 6 (depends on 5)

Use of a DNA sequence according to claim 5 for the inhibition of the translation of protein histidine phosphatase, for the modulation of ATP-citratelyase (EC 4.1.3.8) activity.

### Claim 7 (depends on 1)

Use of a compound according to claim 1 for the manufacture of a medicament for the treatment of pathophysiologic conditions susceptible to the modulation of ATP-citrate-lyase (EC 4.1.3.8) activity.

### Claim 8 (depends on 7)

Use of a compound according to claim 7, wherein the pathophysiologic condition is selected from the group of hyperlipidaemia, hypercholesterolaemia, cardiovascular diseases, obesity, inflammatory diseases, tumors, diseases of the central nervous system, and hypocitraturia.

### Claim 9 (depends on 1)

Use of a compound according to claim 1 for the manufacture of a medicament for controlling weight, promoting fat loss and for appetite suppression.
